PAGKYPRIOS SYNDESMOS KARKINOPATHON KAI FILON 1986

Their core work

PASYKAF (Pan-Cypriot Association of Cancer Patients and Friends) is a non-profit patient advocacy organization founded in 1986 in Nicosia, Cyprus, representing cancer patients and their families. In EU research projects, they serve as a patient community gateway — providing access to real patients for clinical validation, facilitating voluntary health data donation, and grounding AI and digital health tools in the lived experience of people with cancer. They have contributed to projects developing AI-powered cancer imaging diagnostics (INCISIVE) and smart home health monitoring systems for at-risk populations (GATEKEEPER), representing patient interests while enabling real-world deployment and ethical oversight. Their core value to research consortia is trust: they bridge the gap between technology developers and the patient populations those technologies must ultimately serve.

What they specialise in

How they've shifted over time

PASYKAF entered H2020 research through a broad social and health risk early-detection lens with GATEKEEPER (2019), focusing on smart home interventions for people facing general health vulnerabilities — suggesting an initial role as a community deployment partner for digital health pilots. By 2020, with INCISIVE, their involvement sharpened dramatically toward cancer-specific AI diagnostics: the keyword set shifted to breast, colorectal, and lung cancer, with explicit mention of data donation, federated learning, and explainability — pointing to a more active role in data governance and patient representation within AI development workflows. The trajectory is clear: from broad vulnerable-population outreach toward becoming a specialist patient organization embedded in cancer AI research infrastructure.

PASYKAF is positioning itself as a patient data and community access node specifically for cancer-focused AI health tools — future collaborations are likely to center on oncology digital health, explainable AI validation, and ethical frameworks for health data use.

How they like to work

PASYKAF has never led a project — they participate exclusively as consortium members, contributing patient community access rather than technical development. Both of their projects sit within very large consortia, which is typical for organizations whose value is geographic and community representation rather than research output. This makes them a low-friction partner who slots in without organizational overhead, but their contribution is highly context-dependent: they add value only when patient engagement, data donation, or real-world piloting in a Cypriot cancer community is actually needed.

Despite only two projects, PASYKAF has connected with 77 unique consortium partners across 19 countries — a remarkably broad network for a small NGO, explained by the large, multi-country consortia they have joined. Their network is pan-European rather than regionally concentrated.

What sets them apart

PASYKAF fills a role that hospitals and universities cannot easily replicate: long-standing, community-trusted access to cancer patients in Cyprus who are willing to participate in research and donate health data. For AI health projects that need diverse, multi-country patient cohorts, a patient association with 40 years of community presence adds both ethical credibility and practical recruitment capacity. They are one of the very few Cypriot patient-community organizations with proven H2020 participation, making them a logical partner when Cypriot patient data or end-user validation is required by a consortium.

Highlights from their portfolio

• INCISIVE
  Most technically sophisticated project PASYKAF has joined — a multimodal AI cancer imaging repository combining federated learning, blockchain, and XAI, where PASYKAF's role in enabling patient data donation is central to the entire research model.
• GATEKEEPER
  Largest funding received (EUR 220,000) and broadest scope — a smart living demonstrator for health and social risk populations — establishing PASYKAF's track record as a real-world deployment partner before entering cancer-specific AI research.